Analytical Methods in Development and Manufacture of Drugs and Biologics

Analytical methods ensure quality of drugs and biologics. During last 2 decades, paradigm for quality of pharmaceutical products has shifted from ensuring quality by testing representative samples to building quality during manufacture of such products, leading to the concept of Quality by Design (QbD). This course starts with discussing the new paradigm of quality, QbD, and role of analytical methods in ensuring quality.

Methods play a critical role in development and manufacture of drugs and biologics and should be considered as a "Life Cycle" approach throughout the life cycle of a pharmaceutical product. The methods must be suitable for intended purpose during different stages of development and for commercial manufacture of the product. Understanding regulatory expectations and requirements for the methods is important to develop and design methods that are not only suitable for intended purpose, but support manufacturing operations in release of the product in a timely manner. All methods used in manufacturing operations must be maintained in a compliant state with acceptable method performance during life cycle of the product. This course will go into details of the life cycle of analytical methods, including verification, qualification and validation of methods for various stages of product development and for various purposes during manufacturing operations. Appropriate methods attributes and parameters will be discussed that need to be monitored (tracking and trending) to evaluate method performance.

Biologics products being complex and of biological origin, often require biological methods to release starting materials, intermediates and final product. Biological methods or bioassays with large inherent variability have challenges in developing appropriate method so that these are suitable for intended purpose. Focus on science and regulatory expectations during product development is essential to develop appropriate biological methods. This course will further go into the challenges, regulatory expectations and myths about bioassays with focus on developing suitable bioassays for intended purposes.

Upon completing this course the participants will understand:

• Ensuring quality by the new paradigm of Quality by Design(QbD)
• Building quality in the product
• Analytical Method Life Cycle during Product Development and commercial Manufacturing
• Regulatory Expectations and Requirements for the Methods during Product Development
• Methods Verification, Qualification and Validation with Examples
• Methods Validation Characteristics – Robustness, Specificity, Accuracy, Precision, Linearity, Limit of Detection, Limit of Quantitation, Range
• Tracking and Trending of Method Performance
• Challenges with Biological Methods or Bioassays
• Myths and Regulatory Expectations about Bioassays
• Potency Tests for complex Biological Products
• Regulatory Expectations for a Potency test
• Role of Critical Reagents, Reference Standards and Controls and their Development and Qualification
• Risks and Inherent Variability of Analytical Methods
• Designing Methods “Suitable for Intended Purposes” to Mitigate Risks due to Errors and Out of Specification (OOS) Results
• Changes to Approved Methods – Change Control, Comparability Protocols
• How to Continuously Monitor Method Performance and achieve sustainable compliance of methods for regulatory requirements?

….much, much more

Who Will Benefit:

• Pharmaceutical Industry
• Biotech Industry
• Managers and Scientists involved in Drug Development
• Analytical Development Scientists involved in method development, qualification and validation of methods
• Quality Control Scientists Involved in Performing Routine Testing and Monitoring Method Performance
• Quality Assurance Staff for Informed Review of Data and for Managing and Providing Oversights on Investigations, Change Control, etc.

Rajesh K. Gupta has a Ph.D. in microbiology and is the Principal Consultant at the Biologics Quality & Regulatory Consultants, LLC. He has more than 35 years' experience in the development, production, testing and regulation of biologics, working at both the regulatory agencies and the industry.

At FDA, CBER, he was a Deputy Director and the Lab Chief in the Division of Biological Standards and Quality Control, managing lot release of biological products, regulatory reviews of analytical methods in the biologics license applications (BLA), generation of reference standards and development of new methods.

In his previous jobs, he worked at the Biologics Consulting Group, Wyeth, Chiron, Massachusetts Public Health Labs and National Institutes of Health (NIH), in the USA and at National Institute of Immunology and Central Research Institute in India. His major accomplishments are in sterility assurance for biological products, adjuvants and delivery systems for vaccines, polysaccharide-protein conjugate vaccines, combination vaccines and development and validation of analytical methods. In these areas, he has published more than 100 papers in peer reviewed journals and books and has made numerous presentations at scientific and regulatory meetings.

For Registration -  http://www.complianceonline.com/pharma-biotech-analytical-method-development-qbd-workshop-by-ex-fda-seminar-training-80402SEM-prdsm?channel=speedycourse         

Note: Use coupon code  NB5SQH8N  and get 10% off on registration.